Elections to the
                       European Association of Percutaneous
                       Cardiovascular Interve...
GENERAL CV (300 words max)


Prof. Stephan Windecker
Date of birth:                12 January 1964
Marital status:        ...
Previous experience in EAPCI, ESC or your National Bodies?

President of the Swiss Working Group of Interventional Cardiol...
Why should you be elected? (25 lines words max)?

Aims:
   - to foster clinical research and the academic profile of EAPCI...
Upcoming SlideShare
Loading in …5
×

EAPCI elections: CV Windecker

652 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
652
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

EAPCI elections: CV Windecker

  1. 1. Elections to the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Board 2009-2011 Application for the following position in the EAPCI Board: Secretary YOUR IDENTITY Name: Stephan Windecker Current Position: Director, Invasive Cardiology Country: Switzerland 1 EAPCI Board elections 2009 - Applications
  2. 2. GENERAL CV (300 words max) Prof. Stephan Windecker Date of birth: 12 January 1964 Marital status: married with Isabelle Windecker-Gétaz Children: Caroline Alexandra Daniel Citizenship: Swiss DIPLOMAS 1992 Doctor of Medicine (MD degree) University of Heidelberg, Germany 2006 Professor of Medicine Bern University Hospital, Switzerland PROFESSIONAL APPOINTMENTS 1994-1999 Cardiology Fellow Department of Cardiovascular Diseases Bern University Hospital, Switzerland 1999–current Staff Physician, Invasive Cardiology Department of Cardiovascular Diseases Bern University Hospital, Switzerland 2002-current Director, Invasive Cardiology Department of Cardiovascular Diseases Bern University Hospital, Switzerland 2007- Co-Director, Clinical Research in Cardiology Department of Cardiovascular Diseases Bern University Hospital, Switzerland 2007- Executive Board Member, Clinical Trials Unit Bern University Hospital, Switzerland HONORS AND AWARDS 1988 Fulbright Scholarship 1990 American Medical Association/ Educational Research Fund - Award 1993 Alpha Omega Alpha Honor Medical Society 2006 I2-Summit “Innovator of 2005” Award American College of Cardiology, USA 2 EAPCI Board elections 2009 - Applications
  3. 3. Previous experience in EAPCI, ESC or your National Bodies? President of the Swiss Working Group of Interventional Cardiology and Acute Coronary Syndromes Member of the ESC Press Committee Publications (please list 10 max) 1. Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, Togni M, Billinger M, Tüller D, Seiler C, Roffi M, Corti R, Sütsch G, Maier W, Lüscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62 2. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg R., Hess OM, Boersma E, Meier B, Windecker S, Serruys P. Early and Late Coronary Stent Thrombosis of Sirolimus-Eluting and Paclitaxel-Eluting Stents in Routine Clinical Practice: Data from a Large Two-Institutional Cohort Study. Lancet 2007;369:667-78 3. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess OM, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis following drug-eluting stent implantation. Circulation 2007;115:2426-34 4. Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, Vogel R, Seiler C, Eberli FR, Maier W, Corti R, Roffi M, Lüscher T, Garachemani A, Hess OM, Wandel S, Jüni P, Meier B, Windecker S. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 2007;50:1123-31 5. Outcomes associated with drug-eluting and bare metal stents: a collaborative network meta- analysis. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer M, Stone G, Leon M, de Lezo S, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen M, Cervinka P, Petronio AS, Nordmann A, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Lancet 2007;370:937-48 6. Billinger M, Beutler J, Taghetchian K, Remondino A, Wenaweser P, Cook S, Togni M, Seiler C, Stettler C, Eberli FR, Lüscher T, Wandel S, Jüni P, Meier B, Windecker S. Two year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J 2008;29:718-25 7. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, Pfisterer M, Stone GW, Leon M, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp, Kelbaeck H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, de Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Jüni P. Drug-eluting stents versus bare metal stents in diabetic patients: collaborative network meta-analysis. BMJ 2008;337: 8. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys P, Windecker S. Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4 Year Results From a Large Two-Institutional Cohort Study. J Am Coll Cardiol 2008;52:1134-40 9. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer For Coronary Revascularisation: A Randomised Controlled Trial. The Lancet 2008;372:1163-73 10. Authors/Task Force Members Daemen J, Simoons ML, Wijns W; Baczynsak A, Bagust A, Bos G, Boam A, Bowen J, Braunwald E, Camenzind E, Carter A, Chevalier B, DiMario C, Fajadet J, Ghislain J, Gitt A, Guagliumi G, Hillege H, James S, Jüni P, Kastrati A, Kloth S, Kristensen SD, Krucoff M, Legrand V, Lekehal M, Pfisterer M, Raveau-Landon C, Rothman M, Serruys PW, Silber S, Steg PG, Tariah I, Wallentin L, Windecker S. ESC Forum On Drug-Eluting Stents. Eur Heart J 2008 3 EAPCI Board elections 2009 - Applications
  4. 4. Why should you be elected? (25 lines words max)? Aims: - to foster clinical research and the academic profile of EAPCI - to participate in the leadership of EAPCI - to competitively position EAPCI among other international associations Qualification: - director of invasive cardiology at an academic institution - clinical expertise in a broad array of invasive cardiology, including percutaneous coronary interventions, transcatheter aortic and pulmonary valve implantation, percutaneous treatment of structural heart disease defects 4 EAPCI Board elections 2009 - Applications

×